Pharmafile Logo
Pharmafocus logo
Advanced Search

CMA

Showing 8 posts of 8 posts found.

Aspen Pharmacare to pay £8 million after colluding to rip off NHS

August 14, 2019
Research and Development Addison's disease, Aspen Pharmacare, CMA, NHS, pharma

South African firm Aspen Pharmacare has agreed to pay £8 million to Britain’s NHS over a dispute about overpayment. The …

News
nhs_trees_brett_wells_source_web

NHS faced with 5,700% increase in drug price, finds CMA

November 21, 2017
Manufacturing and Production, Medical Communications CMA, Concordia, biotech, drugs, pharma, pharmaceutical

The Competition and Markets Authority (CMA) has pulled up Concordia as, provisionally, being found to have raised the price of …

News
pounds_stacked

Regulators get aggressive on matters excessive

June 29, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CMA, Drug pricing, European Commission, Pfizer, aspen

Gustaf Duhs, Partner at Stevens & Bolton, discusses the recent cases of regulators becoming firmer with drug companies over their …

Feature
cma_logo

CMA accuses Concordia and Actavis of illegal agreement to maintain high prices

March 3, 2017
Medical Communications, Sales and Marketing Actavis UK, CMA, Concordia, competition and markets authority

The Competition and Markets Authority (CMA) has alleged that Concordia and Actavis UK entered into a clandestine agreement to maintain …

News

Actavis UK overcharged NHS with 12,000% price hike, watchdog says

December 16, 2016
Medical Communications, Sales and Marketing Actavis, CMA, NHS

Actavis UK has been accused by the Competition and Markets Authority (CMA) of overcharging the NHS by selling its hydrocortisone …

News

Pfizer slapped with record £84.2 million fine for 2,600% price increase

December 7, 2016
Medical Communications, Research and Development CMA, Flynn Pharma, Pfizer, fine

Pfizer has been hit with a record fine by The Competition and Markets Authority for the increase in the price …

News
pfizerbrussels

Pfizer fined for epilepsy drug price increase by UK antitrust regulator

April 15, 2016
Medical Communications CMA, Flynn Pharma, Pfizer, antitrust, competition and markets authority, epilepsy, fine, flynn

Pfizer has been fined for unfairly increasing the price of epilepsy drug Epanutin (phenytoin sodium) by the UK Competition and …

News

Pfizer and Flynn rapped for overcharging on anti-epilepsy drug

August 6, 2015
Manufacturing and Production, Sales and Marketing CMA, Drug pricing, Flynn Pharma, Pfizer, competitions markets authority, epilepsy, generics, phenytoin, pricing

Pharma firms Pfizer and Flynn Pharma have been accused by the UK’s competition watchdog of charging ‘excessive and unfair’ prices …

News

Latest content

Sanofi shares results from phase 2 trial for frexalimab in MS treatment

July 1, 2024

EMA accepts AstraZeneca’s regulatory submission for sipavibart for COVID-19 prevention

July 1, 2024

Eisai and Biogen’s Leqembi launched for Alzheimer’s treatment in China

June 28, 2024

AbbVie’s Tepkinly gains positive CHMP opinion for follicular lymphoma treatment

June 28, 2024

IDEAYA Biosciences announces first-patient-in for phase 1 clinical trial evaluating IDE397 and Trodelvy combination in MTAP-deletion bladder cancer

June 27, 2024